7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,547.22

+1,064.71

+1.39%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Delayed Quote USD

MiNK Therapeutics, Inc. (INKT)

10.53 -0.35 (-3.17%)

At close: October 30 at 4:00:01 PM EDT

Loading Chart for INKT

Chart Range Bar

Interval:

In partnership with ChartIQ

MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026

MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026

MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy

MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy

MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript

MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript

MiNK Therapeutics Inc (INKT) (Q2 2026) Earnings Call Highlights: AGENT-797 Shows Early Promise ...

MiNK Therapeutics Inc (INKT) (Q2 2026) Earnings Call Highlights: AGENT-797 Shows Early Promise ...

MiNK Therapeutics Q2 Earnings Call Highlights

MiNK Therapeutics Q2 Earnings Call Highlights

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications

MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications

We're Not Very Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Rate

We're Not Very Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Rate

MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Strategic Advances and Financial ...

MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Strategic Advances and Financial ...

MiNK (INKT) Q4 2025 Earnings Call Transcript

MiNK (INKT) Q4 2025 Earnings Call Transcript

Mobilize your Website

View Site in Mobile | Classic

Share by: